摘要:
The present disclosure provides a process for the preparation of crystalline Form C of Compound II:
comprising: (1) adding Compound II to from about 0.4% v/v wet methyl tert-butyl ether (MTBE) to about 1.5% v/v wet MTBE to provide a reaction mixture; (2) refluxing the reaction mixture; (3) cooling the reaction mixture to about room temperature; and (4) isolating the crystalline Form C of Compound II from the reaction mixture.
摘要:
or a salt thereof, active on the receptor protein kinases c-Kit and/or c-Fms and/or Flt3. The disclosure also provides compounds and processes for the preparation of the compounds that are synthetic intermediates to the compound of formula I.
摘要:
or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein Z2, Z3, and Z5 are as described herein, compositions thereof, and uses thereof.
摘要:
Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
摘要:
Compounds active on the receptor protein tyrosine kinases c-kit and/or c-fms are provided herewith. Also provided herewith are compositions useful for treatment of c-kit mediated diseases or conditions and/or c-fms-mediated diseases or conditions, and methods for the use thereof.
摘要:
Compounds active on protein kinases and methods for regulating protein kinase pathways are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.